The concept of combining HSP90 inhibition with BRAF inhibition appeared more than a decade ago and despite seemingly favorable results in early preclinical studies, this combination strategy has yet to be developed further within the thyroid cancer field. Here, BRAF is linked to thyroid gland carcinoma.